BioMarin's Q4: Records Shattered, Pipeline Firing

BioMarins Q4 and full year 2025 earnings shattered records with $3.22 billion in revenues, a 13% increase from last year. Voxzogo led the growth with 26% to $927 million, while enzyme therapies climbed 9%. Operational improvements boosted profitability and cash flow to $828 million, up 45%. In Q4, revenues surged 17% to $875 million, driven by Voxzogos 31% growth and enzyme therapies 13%. Palynziq stood out with 25% growth. Voxzogos global sales, 73% from outside the US, showcased their international reach. For 2026, BioMarin projects total revenues between $3.325 billion and $3.425 billion, with enzyme therapies expected at $2.225 to $2.275 billion and Voxzogo at $975 million to $1.025 billion. Non-GAAP earnings per share are projected at $4.95 to $5.15. The pipeline is robust, with pivotal data soon for Voxzogo in hypochondroplasia, a Phase two study starting for next-gen BMN333 in achondroplasia, and an adolescent label for Palynziq by late February. The Amicus deal adds Galafold and Pombiliti/Opfolda to their enzyme lineup, promising faster growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bcfa7590c454be93